Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
BaumeierCSaussenthalerSKammelAJhnertMSchlterLHesseDet al
Try our Virtual Consultation tool to get personalized recommendations
Tirzepatide received FDA approval as Mounjaro in May 2022 for type 2 diabetes mellitus and as Zepbound in November 2023 for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity
Tirzepatide is a novel medication that acts as a dual incretin mimetic, targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors
Semaglutide is a standard treatment for type 2 diabetes
US$ 27.17
US$ 26.00
US$ 29.50
US$ 26.74
US$ 23.39
US$ 24.24
US$ 28.45
